Rapaprutug Biosimilar Monoclonal Antibody (Lysyl-tRNA Synthetase) for Research

Cat No.: GMP-Bios-INN-1358

Anti-KARS1 therapeutic antibody (Pre-made Rapaprutug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Rapaprutug (development code ZMA001) is a monoclonal antibody targeting KARS1. It is developed by National Heart, Lung, and Blood Institute (NHLBI) for Pulmonary Arterial Hypertension PAH in Phase I development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1358-1mg 1mg 3090
GMP-Bios-INN-1358-10mg 10mg
GMP-Bios-INN-1358-100mg 100mg
GMP-Bios-INN-1358-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Rapaprutug biosimilar, Whole mAb, Anti-KARS1 Antibody: Anti-KARS/KARS1/Lysine--tRNA ligase/Lysyl-tRNA synthetase (LysRS) therapeutic antibody
INN Name Rapaprutug
Target KARS1
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC